News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shire To Pay $4.2 Billion For Rare Disease Firm ViroPharma Incorporated (VPHM)



11/11/2013 7:11:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

London-listed Shire is buying ViroPharma for $4.2 billion, its biggest deal yet to strengthen its portfolio of lucrative drugs to treat rare diseases, which are attracting increasing attention from drugs companies as patents expire on their older treatments. Several companies including France's Sanofi, according to reports, were interested in ViroPharma, which makes Cinryze for the treatment of immune disorder hereditary angioedema. Treatments for such rare disorders can command huge prices, running into hundreds of thousands of dollars a year per patient.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at BusinessWeek
Read at New York Times
Read at RTT News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES